Life Technologies Partners with Ridom and Releases SeqSphere+ Software to
Speed and Simplify Bacterial Typing
CARLSBAD, Calif., April 18, 2013
CARLSBAD, Calif., April 18,2013 /PRNewswire/ --Life Technologies
Corporation(NASDAQ: LIFE) announced today that it is partnering with Ridom
GmbH (Munster, Germany) to make SeqSphere^+ whole genome bacterial typing
software available for Ion Torrent users. This software enables any lab to
perform fast, affordable, and automated high-resolution bacterial typing on
the Ion Personal Genome Machine^® (PGM™) sequencer.
Up to now, typing methods have lacked discriminatory power, been difficult to
standardize, or been labor intensive. SeqSphere^+ automated software enables
any microbiologist to use a genome-wide approach, typing hundreds to thousands
of genes, resulting in higher discrimination and more accurate typing of
"It is our aim to deliver a fully integrated turnkey solution for public
health and clinical research microbiology," said Dr. Dag Harmsen, University
Hospital Muenster, Germany, who is also co-managing director of Ridom and was
central in sequencing the deadly E. coli O104:H4 that killed more than 40
people in Germany in 2011. "Together our solution provides an easy workflow
with nearly no user intervention, delivering high-quality results using the
Ion PGM System. We are excited and feel privileged to work together with the
developer/vendor of the fastest evolving benchtop NGS platform, Ion Torrent."
The Ion PGM Sequencer is already in use for subtyping flu viruses by the
Global Influenza Network, a collaborative effort between Life Technologies and
scientists at a number of the world's leading government public health
organizations, veterinary agencies and research institutes. The network
focuses on increasing speed, cost effectiveness and accuracy of influenza
monitoring and vaccine development. Members share tools, experience and data
using the PathAmp™ FluA Reagents and the Ion PGM™ sequencer.
Bacterial typing using Ion Torrent technology is fast and affordable.
Bacterial typing can be performed in less than a day from library prep to data
analysis. The complete solution includes:
oIon Xpress® Plus Fragment Library Kit for library construction,
oIon Chef® System for high throughput sequencing or Ion OneTouch® 2 System
to automate template preparation,
oIon PGM® Sequencer and Ion Chips with the 400 base-pair kit for long,
accurate reads in as little as three hours,
oTorrent Suite Software & Ridom SeqSphere^+ Software for easy data analysis
SeqSphere^+ features include:
DNA re-sequencing editor edits and analyzes de novo (.ace) or reference-mapped
assemblies (.bam) of NGS data (e.g., MLST, MLST^+). Auto-correction of
homopolymer related InDel errors.
Analytical tools select data entries from a comparison table for
epidemiologic, evolutionary or functional analysis. Cluster and visualize data
entries by using minimum spanning or UPGMA/Neighbor Joining trees.
Database to store, search, retrieve, export and create reports from your
epidemiologic and DNA sequence data stored in an integrated database. Search
new sequence entries against stored data.
Bacteria typing is automatically performed with user defined quality
parameters (e.g., coverage, stop codons, frame shift detection, etc.) using
public or self-defined query libraries and task templates.
Products referenced above are For Research Use only, not for use in diagnostic
About Life Technologies
Life Technologies Corporation(NASDAQ:LIFE) is a global biotechnology company
that is committed to providing the most innovative products and services to
leading customers in the fields of scientific research, genetic analysis and
applied sciences. With a presence in more than 180 countries, the company's
portfolio of 50,000 end-to-end solutions is secured by more than 5,000 patents
and licenses that span the entire biological spectrum -- scientific
exploration, molecular diagnostics, 21^stcentury forensics, regenerative
medicine and agricultural research. Life Technologies has approximately 10,000
employees and had sales of $3.8 billion in 2012.
Life Technologies' Safe Harbor Statement
This press release includes forward-looking statements about Life
Technologies' anticipated results that involve risks and uncertainties. Some
of the information contained in this press release, including, but not limited
to, statements as to industry trends and Life Technologies' plans, objectives,
expectations and strategy for its business, contains forward-looking
statements that are subject to risks and uncertainties that could cause actual
results or events to differ materially from those expressed or implied by such
forward-looking statements. Any statements that are not statements of
historical fact are forward-looking statements. When used, the words
"believe," "plan," "intend," "anticipate," "target," "estimate," "expect" and
the like, and/or future tense or conditional constructions ("will," "may,"
"could," "should," etc.), or similar expressions, identify certain of these
forward-looking statements. Important factors which could cause actual results
to differ materially from those in the forward-looking statements are detailed
in filings made byLife Technologies with the Securities and Exchange
Commission.Life Technologies undertakes no obligation to update or revise any
such forward-looking statements to reflect subsequent events or circumstances.
Life Technologies Contact:
SOURCE Life Technologies Corporation
Press spacebar to pause and continue. Press esc to stop.